Cerus Corp
NASDAQ:CERS
Cerus Corp
Other
Cerus Corp
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cerus Corp
NASDAQ:CERS
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Other
-$5.1m
|
CAGR 3-Years
43%
|
CAGR 5-Years
-91%
|
CAGR 10-Years
N/A
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Other
-$8.8m
|
CAGR 3-Years
33%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Other
-$20.2m
|
CAGR 3-Years
27%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-7%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Other
-$28.5m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-8%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Other
-$11.3m
|
CAGR 3-Years
31%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
Cerus Corp
Glance View
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 294 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.
